← Leaderboards
John G. Gerber
University Of Colorado Denver
$1,597,914
Attributed
$1,597,914
Total exposure
8
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $18.4K · FY2005–06$20K$15K$10K$5K$0
'05
'06
Funding mix
By agency
NIH$1,597,914 · 8
By mechanism
M01$1,597,914 · 8
Top collaborators
No co-investigators on record.
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Robert Turner Schooley$73,100,957
- Peter A Gottlieb$9,273,760
- Elizabeth Connick$17,363,459
- David Ross$13,236,658
- Richard Martin$417,265
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchDrug InteractionsClinical Trial Phase IAids TherapyHiv InfectionsHuman Therapy EvaluationPharmacokineticsRitonavirCombination ChemotherapyProtease InhibitorSaquinavirDrug MetabolismRifabutinIndinavirMethadoneClarithromycinNelfinavirDrug Abuse ChemotherapyDrug Administration Rate /DurationCytochrome P450Antihyperlipoproteinemic AgentBlood ChemistryPatient Oriented Research
Grant awards (26)
EFFECT OF COMBTHERW/FISH OIL SUPP&FENOFIBRATE ON TG LEVELS IN SBJCTS ON HAART$1,829
M01 · FY2006 · RR · contact PI
EFFECT OF COMBTHERW/FISH OIL SUPP&FENOFIBRATE ON TG LEVELS IN SBJCTS ON HAART$8,294
M01 · FY2005 · RR
ACTG A5165: STUDY OF DAPD VS DAPD + MMF IN TREATMENT-EXPERIENCED SUBJECTS$5,529
M01 · FY2005 · RR
PREDICTIVE VALUE OF PHARMACOKIN-ADJC12H/1C50 ON RESPONSE TO PROTEASE INHIBITORS$4,609
M01 · FY2005 · RR
ACTG A5165: STUDY OF DAPD VS. DAPD + MMF IN TREATMENT$17,451
M01 · FY2004 · RR
Predictive Value of Pharmacokin-Adj.C12h/1C50$2,014
M01 · FY2004 · RR
RIFABUTIN PROBE TO MEASURE CYP3A4 ACTIVITY$190,747
M01 · FY2002 · RR
ACTG 365 PHARMACOKINETIC INTERACTION OF INDINAVIR &RIFABUTIN$190,747
M01 · FY2002 · RR
PROTEASE INHIBITORS AND METHADONE METABOLISM IN HIV +$190,747
M01 · FY2002 · RR
PROTEASE INHIBITORS AND LIPID LOWERING AGENTS$190,747
M01 · FY2002 · RR
PROTEASE INHIBITORS AND METHADONE METABOLISM IN HIV +$190,747
M01 · FY2001 · RR
ACTG 365 PHARMACOKINETIC INTERACTION OF INDINAVIR &RIFABUTIN$190,747
M01 · FY2001 · RR
RIFABUTIN PROBE TO MEASURE CYP3A4 ACTIVITY$190,747
M01 · FY2001 · RR
PROTEASE INHIBITORS AND LIPID LOWERING AGENTS$190,747
M01 · FY2001 · RR
RIFABUTIN PROBE TO MEASURE CYP3A4 ACTIVITY$0
M01 · FY2001 · RR
ACTG 365 PHARMACOKINETIC INTERACTION OF INDINAVIR &RIFABUTIN$0
M01 · FY2001 · RR
PROTEASE INHIBITORS AND METHADONE METABOLISM IN HIV +$0
M01 · FY2001 · RR
PROTEASE INHIBITORS AND LIPID LOWERING AGENTS$0
M01 · FY2001 · RR
ACTG 365 PHARMACOKINETIC INTERACTION OF INDINAVIR &RIFABUTIN$32,212
M01 · FY2000 · RR
PROTEASE INHIBITORS AND LIPID LOWERING AGENTS$0
M01 · FY2000 · RR
PROTEASE INHIBITORS AND LIPID LOWERING AGENTS$0
M01 · FY2000 · RR
RIFABUTIN PROBE TO MEASURE CYP3A4 ACTIVITY$0
M01 · FY2000 · RR
ACTG 365 PHARMACOKINETIC INTERACTION OF INDINAVIR &RIFABUTIN$0
M01 · FY2000 · RR
PROTEASE INHIBITORS AND METHADONE METABOLISM IN HIV +$0
M01 · FY2000 · RR
PROTEASE INHIBITORS AND METHADONE METABOLISM IN HIV +$0
M01 · FY2000 · RR
RIFABUTIN PROBE TO MEASURE CYP3A4 ACTIVITY$0
M01 · FY2000 · RR